nach oben

27.03.2024 | Review

Primary Biliary Cholangitis: Updates in Management and Goals of Treatment

verfasst von: Kaitlyn Carlson, Madeleine Hines Salge, George Cholankeril

Erschienen in: Current Hepatology Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Primary biliary cholangitis (PBC) is a chronic autoimmune disease of the liver characterized by cholestasis and destruction of bile ducts. Goals of treatment include normalization of liver enzymes and prevention of progression to cirrhosis as well as symptom control. The purpose of this review is to summarize the current state of treatment of primary biliary cholangitis.

Recent Findings

In 2021, AASLD released a statement recommending fibrates as an off-label alternative for PBC patients with inadequate response or contraindications to approved therapies. Caution should be used when considering OCA in advanced liver disease. Multiple other therapies for PBC are in phase III trials including PPAR agonists and IBAT inhibitors.

Summary

There are two FDA-approved treatments for primary biliary cholangitis, ursodeoxycholic acid (UDCA) and obeticholic acid (OCA). Obeticholic acid is used when there is inadequate response to UDCA, and fibrates can also be considered as off-label alternatives in the setting of inadequate response to first-line therapy. Several other classes of drugs are in development for primary biliary cholangitis including multiple in phase III trials.

Trivella J, John BV, Levy C. Primary biliary cholangitis: epidemiology, prognosis, and treatment. Hepatol Commun. 2023;7(6):e0179. https://doi.org/10.1097/HC9.0000000000000179.CrossRefPubMedPubMedCentral

Current Medical Diagnosis & Treatment 2023 | AccessMedicine | McGraw Hill Medical. Accessed June 14, 2023. https://accessmedicine.mhmedical.com/book.aspx?bookID=3212

Younossi ZM, Bernstein D, Shiffman ML, et al. Diagnosis and management of primary biliary cholangitis. Am J Gastroenterol. 2019;114(1):48–63. https://doi.org/10.1038/s41395-018-0390-3.CrossRefPubMed

Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the american association for the study of liver diseases. Hepatology. 2019;69(1):394. https://doi.org/10.1002/hep.30145.CrossRefPubMed

Lu M, Zhou Y, Haller IV, et al. Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. Clin Gastroenterol Hepatol. 2018;16(8):1342–1350.e1. https://doi.org/10.1016/j.cgh.2017.12.033.CrossRefPubMed

Danford CJ, Trivedi HD, Papamichael K, Tapper EB, Bonder A. Osteoporosis in primary biliary cholangitis. World J Gastroenterol. 2018;24(31):3513–20. https://doi.org/10.3748/wjg.v24.i31.3513.CrossRefPubMedPubMedCentral

Seki A, Ikeda F, Miyatake H, et al. Risk of secondary osteoporosis due to lobular cholestasis in non-cirrhotic primary biliary cholangitis. J Gastroenterol Hepatol. 2017;32(9):1611–6. https://doi.org/10.1111/jgh.13746.CrossRefPubMed

Chalifoux SL, Konyn PG, Choi G, Saab S. Extrahepatic manifestations of primary biliary cholangitis. Gut Liver. 2017;11(6):771–80. https://doi.org/10.5009/gnl16365.CrossRefPubMedPubMedCentral

Floreani A, Mangini C, Reig A, et al. Thyroid dysfunction in primary biliary cholangitis: a comparative study at two european centers. Am J Gastroenterol. 2017;112(1):114–9. https://doi.org/10.1038/ajg.2016.479.CrossRefPubMed

10.

Werner M, Prytz H, Ohlsson B, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol. 2008;43(10):1232–40. https://doi.org/10.1080/00365520802130183.CrossRefPubMed

11.

Czaja AJ. Diagnosis and management of the overlap syndromes of autoimmune hepatitis. Can J Gastroenterol. 2013;27(7):417–23. https://doi.org/10.1155/2013/198070.CrossRefPubMedPubMedCentral

12.

• Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med. 1994;330(19):1342–7. https://doi.org/10.1056/NEJM199405123301903. Landmark randomized-controlled trial showing decreased progression and need for transplant in PBC patients treated with UDCA.CrossRefPubMed

13.

Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2007;5(11):1313–5. https://doi.org/10.1016/j.cgh.2007.07.015.CrossRefPubMed

14.

Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, et al. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol. 2020 Jul;115(7):1066–74. https://doi.org/10.14309/ajg.0000000000000557.CrossRefPubMed

15.

• Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;147(6):1338–1349.e5; quiz e15. https://doi.org/10.1053/j.gastro.2014.08.029. Meta-analysis showing that ALP and bilirubin are surrogate disease markers and can be used to predict outcomes.CrossRefPubMed

16.

• Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631–43. https://doi.org/10.1056/NEJMoa1509840. Phase III trial showing benefit of OCA for inadequate responders to UDCA and those who cannot tolerate UDCA.CrossRefPubMed

17.

Jang H, Han N, Staatz CE, Kwak JH, Baek IH. Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2023;47(10):102227. https://doi.org/10.1016/j.clinre.2023.102227.CrossRefPubMed

18.

Eaton JE, Vuppalanchi R, Reddy R, Sathapathy S, Ali B, Kamath PS. Liver injury in patients with cholestatic liver disease treated with obeticholic acid. Hepatology. 2020;71(4):1511–4. https://doi.org/10.1002/hep.31017.CrossRefPubMed

19.

• Corpechot C, Chazouillères O, Rousseau A, et al. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med. 2018;378(23):2171–81. https://doi.org/10.1056/NEJMoa1714519. The BEZURSO trial; a landmark trial showing improved liver tests in poor-responders to UDCA with bezafibrate + UDCA versus placebo + UDCA.CrossRefPubMed

20.

• Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology. 2022;75(4):1012. https://doi.org/10.1002/hep.32117. AASLD Practice Guidance Update recommending fibrates as off-label therapy for non-responders to UDCA and includes warning against OCA use in advanced liver cirrhosis.

21.

Singh A, Fritze D, Mansouri M, et al. Characteristics and outcomes of liver transplantation for primary biliary cholangitis in young patients: analysis of the united network for organ sharing database. Transplantation. 2019;103(6):1191. https://doi.org/10.1097/TP.0000000000002501.CrossRefPubMed

22.

Corpechot C, Chazouillères O, Belnou P, et al. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. J Hepatol. 2020;73(3):559–65. https://doi.org/10.1016/j.jhep.2020.03.043.CrossRefPubMed

23.

Santiago P, Scheinberg AR, Levy C. Cholestatic liver diseases: new targets, new therapies. Therap Adv Gastroenterol. 2018;11:1756284818787400. https://doi.org/10.1177/1756284818787400.CrossRefPubMedPubMedCentral

24.

• ENHANCE: safety and efficacy of seladelpar in patients with primary biliary cholangitis—a phase 3, international, randomized, placebo-controlled study. Gastroenterol Hepatol (N Y). 2021;17(2 Suppl 3):5–6. Ongoing phase III trial investigating PPAR agonist seladelpar for PBC.

25.

Bowlus CL, Galambos MR, Aspinall RJ, et al. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol. 2022;77(2):353–64. https://doi.org/10.1016/j.jhep.2022.02.033.CrossRefPubMed

26.

• Schattenberg JM, Pares A, Kowdley KV, et al. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021;74(6):1344–54. https://doi.org/10.1016/j.jhep.2021.01.013. Phase II trial for elafibrinor showing improvement in ALP and other secondary endpoints.CrossRefPubMed

27.

• Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2023; https://doi.org/10.1056/NEJMoa2306185. Phase 3 trial for elafibrinor showing improvement in ALP and other biochemical indicators.

28.

Kowdley KV, Minuk GY, Pagadala MR, Gulamhusein A, Swain MG, Neff GW, et al. The nonsteroidal farnesoid x receptor (FXR) agonist cilofexor improves liver biochemistry in patients with primary biliary cholangitis (PBC): A phase 2, randomized, placebo-controlled trial. Hepatology. 2019;70:31A–2A.

29.

Galoosian A, Hanlon C, Zhang J, Holt EW, Yimam KK. Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches. J Clin Transl Hepatol. 2020;8(1):49–60. https://doi.org/10.14218/JCTH.2019.00049.CrossRefPubMedPubMedCentral

30.

Invernizzi P, Carbone M, Jones D, et al. Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial. Liver Int. 2023;15. https://doi.org/10.1111/liv.15596.

31.

• Jones D, Carbone M, Invernizzi P, et al. Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatol Commun. 2023;7(3):e0057. https://doi.org/10.1097/HC9.0000000000000057. In this post-hoc analysis, patients receiving setanaxib 400 twice a day compared to daily or placebo had improvements in all domains of the PBC-40 except itch.CrossRefPubMedPubMedCentral

32.

Maralixibat: First Approval | SpringerLink. Accessed June 7, 2023. https://link.springer.com/article/10.1007/s40265-021-01649-0

33.

Odevixibat: First Approval | SpringerLink. Accessed June 7, 2023. https://link.springer.com/article/10.1007/s40265-021-01594-y

34.

Mayo MJ, Pockros PJ, Jones D, et al. A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis. Hepatol Commun. 2019;3(3):365–81. https://doi.org/10.1002/hep4.1305.CrossRefPubMedPubMedCentral

35.

Mirum Pharmaceuticals, Inc. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Biliary Cholangitis. clinicaltrials.gov; 2023. Accessed June 6, 2023. https://clinicaltrials.gov/ct2/show/NCT05050136

36.

• Levy C, Kendrick S, Bowlus CL, et al. GLIMMER: A randomized phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus. Clin Gastroenterol Hepatol. 2022; https://doi.org/10.1016/j.cgh.2022.10.032. In this phase two trial, linerixibat was associated with improvement in PBC-related itch.

37.

Hirschfield GM, Beuers U, Kupcinskas L, et al. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. J Hepatol. 2021;74(2):321–9. https://doi.org/10.1016/j.jhep.2020.09.011.CrossRefPubMed

38.

Myers RP, Swain MG, Lee SS, Shaheen AAM, Burak KW. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol. 2013;108(6):933–41. https://doi.org/10.1038/ajg.2013.51.CrossRefPubMed

39.

Khanna A, Jopson L, Howel D, et al. Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis: a phase 2 randomized controlled trial. Hepatology. 2019;70(5):1646–57. https://doi.org/10.1002/hep.30099.CrossRefPubMed

40.

Bowlus CL, Yang GX, Liu CH, et al. Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. J Autoimmun. 2019;101:26–34. https://doi.org/10.1016/j.jaut.2019.04.005.CrossRefPubMed

Titel: Primary Biliary Cholangitis: Updates in Management and Goals of Treatment
verfasst von: Kaitlyn Carlson
Madeleine Hines Salge
George Cholankeril
Publikationsdatum: 27.03.2024
Verlag: Springer US
Erschienen in: Current Hepatology Reports
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-024-00667-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen